First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation
Meeting Abstract
Yap, T. A.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Garcia, V. Moreno; Punekar, S. R.; Calvo, E.; Sonpavde, G. P.; Awad, M.; Riess, J. W.; Hernandez-Guerrero, T.; Herzberg, B.; Italiano, A.; Swalduz, A.; LoRusso, P.; Smit, E. F.; Garon, E. B.; Novotny, W.; Guo, R.